Cat. No. | Product name | CAS No. |
DC72045 |
(S)-PM-43I
(S)-PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. (S)-PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research[1]. |
1637532-77-4 |
DC72046 |
PM-81I
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer[1]. |
1637532-83-2 |
DC72210 |
NDI-034858(Zasocitinib)
Featured
NDI034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. |
2272904-53-5 |
DC72211 |
HP590
HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). HP590 shows anti-proliferative activity to gastric cancer cells and induces apoptosis. |
|
DC72355 |
STX-0119
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM. |
851095-32-4 |
DC72356 |
GYY4137
GYY4137 is a novel, water-soluble hydrogen sulfide (H2S)–releasing molecule with vasodilator and antihypertensive activity. GYY4137 shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. GYY4137 also shows anti-inflammatory activity. |
|
DC72357 |
inS3-54-A18
inS3-54A18 is a potent inhibitor of STAT3 with anti-cancer properties. |
|
DC72648 |
Rovadicitinib hydrochloride
Rovadicitinib hydrochloride is a JAK inhibitor with an IC50 value <20 nM. Rovadicitinib hydrochloride also exhibits anti-inflammatory activity. |
1948242-60-1 |
DC72649 |
Nimucitinib
Featured
Nimucitinib is a Janus kinase (JAK) inhibitor. |
2740557-24-6 |
DC72650 |
Pumecitinib
Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity. |
2401057-12-1 |
DC73567 |
ABBV-712
ABBV-712 is a potent, selective inhibitor of tyrosine kinase 2 (TYK2) with EC50 of 0.01 uM, binds and stabilizes the pseudokinase (JH2) domain of TYK2. |
2368945-27-9 |
DC73568 |
ABT-317
ABT-317 (ABT317) is a potent, selective JAK1 inhibitor, inhibits IL-6-stimulated pSTAT3 (TF-1 cells, IC50=16 nM) and IL-2-stimulated pSTAT5 (T-blasts, IC50=30 nM). |
|
DC73569 |
ATI-1777
ATI-1777 is a potent, selective and ATP-competitive JAK1/3 inhibitor with IC50 of 1.5/3.6/7.1/19.0 nM for JAK1/JAK2/JAK3/TYK2, respectively. |
2321488-47-3 |
DC73570 |
AZD0449
AZD0449 (AZD-0449) is a potent and highly selective JAK1 inhibitor with IC50 of 2.4 nM, displays >50-fold selectivity over TYK2 and JAK2, and no inhibition against JAK3. |
1236666-76-4 |
DC73571 |
CPL409116
CPL409116 (CPL 409116) is a potent, competitive, dual JAK and ROCK inhibitor with IC50 of 0.95/5.36//0.87/110.6/106.7 nM for JAK1/JAK2/JAK3/ROCK1/ROCK2, respectively. |
2250013-34-2 |
DC73572 |
MMT3-72
MMT3-72 is a gastrointestinal locally-activating Janus kinase (JAK) inhibitor, readily converted to MMT3-72-M2 in the colon contents (JAK1 IC50=10.8 nM, JAK2 IC50=26.3 nM and TYK2 IC50=91.6 nM). |
2996158-39-3 |
DC73573 |
QL-1200186
QL-1200186 is a potent, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 0.06 nM, targets pseudokinase regulatory domain (Janus homology 2, JH2) of the TYK2 protein. |
|
DC73574 |
Ruxolitinib sulfate
A potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively. |
1092939-16-6 |
DC73575 |
YLIU-5-162-1
YLIU-4-105-1 is a novel type II JAK2 inhibitor, binds to JAK2 kinase domain (JH1), show potential for overcoming acquired resistance to ruxolitinib. |
2417685-83-5 |
DC73576 |
Z583
Z583 is a potent, highly selective JAK3 inhibitor with IC50 of 0.1 nM, 4500-fold selectivity over other JAK subtypes. |
2412569-41-4 |
DC73577 |
DR-1-55
DR-1-55 (DR-155) is a selective STAT3 inhibitor that covalently modifies a cysteine in the SH2 domain of STAT3. |
|
DC73578 |
K1836
K1836 is a small molecule Stattic analog inhibitor of STAT3 signalling. |